In general, the proposed Diversity Plans will not be trial-specific but will rather be plans across a product development program. On this basis, I suggest they would not be expected to be filed in the Trial Master File.
Were a trial-specific Diversity Plan to be created, my suggestion would be to file under 01.01.02 Trial Management Plan on the basis that its purpose is aligned with the definition/purpose of this artifact
or 03.01.01 Regulatory Submission on the basis that it is a trial-related document that is submitted to a regulatory agency (filed to the IND).
The draft guidance seems to suggest that its use will be recommended rather than mandatory, though it does sound as though the FDA are being pressurized to mandate its use.
Any thoughts from others?